Values First Advisors Inc. Sells 7,885 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Values First Advisors Inc. reduced its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) by 30.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 18,234 shares of the company’s stock after selling 7,885 shares during the quarter. Values First Advisors Inc.’s holdings in Scholar Rock were worth $788,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its holdings in Scholar Rock by 29.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 19,850 shares of the company’s stock valued at $858,000 after acquiring an additional 4,457 shares in the last quarter. Moody Aldrich Partners LLC bought a new stake in shares of Scholar Rock during the 4th quarter valued at about $1,201,000. KBC Group NV purchased a new position in shares of Scholar Rock during the fourth quarter valued at about $131,000. Nisa Investment Advisors LLC raised its stake in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after buying an additional 1,031 shares in the last quarter. Finally, Hamilton Lane Advisors LLC purchased a new stake in Scholar Rock in the fourth quarter worth about $1,274,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on SRRK. HC Wainwright raised their target price on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Truist Financial boosted their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Piper Sandler increased their price target on shares of Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Finally, Wedbush reissued an “outperform” rating and set a $47.00 price objective on shares of Scholar Rock in a research note on Wednesday, January 29th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $40.43.

Insider Transactions at Scholar Rock

In related news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the sale, the insider now directly owns 10,850,005 shares of the company’s stock, valued at $417,616,692.45. This trade represents a 3.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 12,539 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $554,223.80. Following the completion of the transaction, the chief financial officer now directly owns 148,549 shares of the company’s stock, valued at approximately $6,565,865.80. This trade represents a 7.78 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 458,974 shares of company stock worth $17,948,788. Corporate insiders own 19.20% of the company’s stock.

Scholar Rock Trading Down 2.9 %

Shares of Scholar Rock stock opened at $37.03 on Wednesday. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The firm’s 50-day moving average is $42.61 and its 200 day moving average is $27.03. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.